Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalStockholderEquity,intangibleAssets,capitalSurplus,totalLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GNRRF,,14587500,1093550,,-2506950,,-2506950,795400,0,-1872150,-1872150,-16800,,,,,0,0,1872150,0,-634800,,-2506950,-2506950,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,en-US,US,EQUITY,False,Delayed Quote,4.55,1629901990,0.0,4.55,4.55,4.55,125,USD,PNK,57888288,-14400000,False,False,PREPRE,4,0.0,4.55 - 4.55,us_market,0,GENEURO,4.55,0.0,0.0,0,0,finmb_49247578,Other OTC,GeNeuro SA,EUR,243,0,1.4100001,0.4490446,3.14 - 4.55,0.0,0.0,3.14,4.55,-0.541,0.502,3.2830303,1.2669699,0.38591477,3.3261764,1.2238238,0.36793712,9.0637455,15,America/New_York,EDT,0.52,,,4.55,3.14,3.283,3.3262,243,,14.59M,,5.17M,42.32%,39.59%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,,,,,,,-7.42M,-8.96M,-0.5410,,,,,,,0.5,,,Value,1228,,7,1,"GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",Plan-les-Ouates,41 22 552 48 00,1,1577750400,1619740800,9,Switzerland,http://www.geneuro.ch,86400,7,3 chemin du PrÃ©-Fleuri,
t-1,GNRRF,7153300.0,14587500,1093550,,-2506950,,-2506950,795400,0,-1872150,-1872150,-16800,,,,,0,0,1872150,0,-634800,,-2506950,-2506950,8306200.0,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,en-US,US,EQUITY,False,Delayed Quote,4.55,1629901990,0.0,4.55,4.55,4.55,125,USD,PNK,57888288,-14400000,False,False,PREPRE,4,0.0,4.55 - 4.55,us_market,0,GENEURO,4.55,0.0,0.0,0,0,finmb_49247578,Other OTC,GeNeuro SA,EUR,243,0,1.4100001,0.4490446,3.14 - 4.55,0.0,0.0,3.14,4.55,-0.541,0.502,3.2830303,1.2669699,0.38591477,3.3261764,1.2238238,0.36793712,9.0637455,15,America/New_York,EDT,0.52,,,4.55,3.14,3.283,3.3262,243,,14.59M,,5.17M,42.32%,39.59%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,,,,,,,-7.42M,-8.96M,-0.5410,,,,,,,0.5,,,Value,1228,,7,1,"GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",Plan-les-Ouates,41 22 552 48 00,1,1577750400,1619740800,9,Switzerland,http://www.geneuro.ch,86400,7,3 chemin du PrÃ©-Fleuri,
t-2,GNRRF,7153300.0,14587500,985000,,-1974200,,-1974200,855600,0,-1857400,-1857400,16800,-32900.0,,,,0,0,1857400,0,-116800,,-1974200,-1974200,8306200.0,1152900.0,14702300.0,4851700.0,6300.0,13157900.0,892300.0,99900.0,-6315000.0,2318900.0,-973400.0,272000.0,10492200.0,2226700.0,15600.0,-973400.0,507300.0,11225700.0,274900.0,170700.0,595800.0,-317150.0,-1250.0,-3828300.0,4209600.0,93700.0,8749950.0,2280400.0,-30650.0,-1897300.0,87550.0,150.0,-712050.0,212800.0,-500.0,8999000.0,en-US,US,EQUITY,False,Delayed Quote,4.55,1629901990,0.0,4.55,4.55,4.55,125,USD,PNK,57888288,-14400000,False,False,PREPRE,4,0.0,4.55 - 4.55,us_market,0,GENEURO,4.55,0.0,0.0,0,0,finmb_49247578,Other OTC,GeNeuro SA,EUR,243,0,1.4100001,0.4490446,3.14 - 4.55,0.0,0.0,3.14,4.55,-0.541,0.502,3.2830303,1.2669699,0.38591477,3.3261764,1.2238238,0.36793712,9.0637455,15,America/New_York,EDT,0.52,,,4.55,3.14,3.283,3.3262,243,,14.59M,,5.17M,42.32%,39.59%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,,,,,,,-7.42M,-8.96M,-0.5410,,,,,,,0.5,,,Value,1228,,7,1,"GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",Plan-les-Ouates,41 22 552 48 00,1,1577750400,1619740800,9,Switzerland,http://www.geneuro.ch,86400,7,3 chemin du PrÃ©-Fleuri,
t-3,GNRRF,7153300.0,14587500,985000,,-1974200,,-1974200,855600,0,-1857400,-1857400,16800,-32900.0,,,,0,0,1857400,0,-116800,,-1974200,-1974200,8306200.0,1152900.0,14702300.0,4851700.0,6300.0,13157900.0,892300.0,99900.0,-6315000.0,2318900.0,-973400.0,272000.0,10492200.0,2226700.0,15600.0,-973400.0,507300.0,11225700.0,274900.0,170700.0,595800.0,-317150.0,-1250.0,-3828300.0,4209600.0,93700.0,8749950.0,2280400.0,-30650.0,-1897300.0,87550.0,150.0,-712050.0,212800.0,-500.0,8999000.0,en-US,US,EQUITY,False,Delayed Quote,4.55,1629901990,0.0,4.55,4.55,4.55,125,USD,PNK,57888288,-14400000,False,False,PREPRE,4,0.0,4.55 - 4.55,us_market,0,GENEURO,4.55,0.0,0.0,0,0,finmb_49247578,Other OTC,GeNeuro SA,EUR,243,0,1.4100001,0.4490446,3.14 - 4.55,0.0,0.0,3.14,4.55,-0.541,0.502,3.2830303,1.2669699,0.38591477,3.3261764,1.2238238,0.36793712,9.0637455,15,America/New_York,EDT,0.52,,,4.55,3.14,3.283,3.3262,243,,14.59M,,5.17M,42.32%,39.59%,,,,,,,,,,,,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,,,,,,,-7.42M,-8.96M,-0.5410,,,,,,,0.5,,,Value,1228,,7,1,"GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",Plan-les-Ouates,41 22 552 48 00,1,1577750400,1619740800,9,Switzerland,http://www.geneuro.ch,86400,7,3 chemin du PrÃ©-Fleuri,
